Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tsan-Jung Yu

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Pediatric Transplantation|October 4, 2007
De novo urothelial carcinoma in a pediatric recipient of living donor kidney graftChan-Yao Wu, Shih-Yuan Hung, Yu-Tsun Su, et al.
Molecules (Basel, Switzerland)|November 11, 2022
WWOX Modulates ROS-Dependent Senescence in Bladder CancerChing-Wen Liu, Po-Hen Chen, Tsan-Jung Yu, et al.
Journal of Clinical Nursing|December 20, 2011
Comparison of health-related quality of life between subjects treated with radical prostatectomy and brachytherapyYu-Hua Lin, Victor Chia-Hsiang Lin, Tsan-Jung Yu, et al.
Cancer Nursing|October 23, 2012
Changes in quality of life among prostate cancer patients after surgeryYu-Hua Lin, Tsan-Jung Yu, Victor Chia-Hsiang Lin, et al.
Urology|February 20, 2004
Synchronous bilateral primary transitional cell carcinoma of the upper urinary tracts: ten patients with more than five years of follow-upChih-Hsiung Kang, Tsan-Jung Yu, Hwei-Ho Hsieh, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 11, 2004
High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablationPo Hui Chiang, Fu Min Fang, Wang Chong Jong, et al.
Oncology Reports|December 28, 2011
p53 codon 72 polymorphism as a progression index for bladder cancerHung-Yu Lin, Chun-Hsiung Huang, Tsan-Jung Yu, et al.
Urologia Internationalis|February 25, 2011
p53 codon 72 polymorphism was associated with vulnerability, progression, but not prognosis of bladder cancer in a Taiwanese population: an implication of structural equation modeling to manage the risks of bladder cancerHung-Yu Lin, Chun-Hsiung Huang, Tsan-Jung Yu, et al.
Molecules (Basel, Switzerland)|June 4, 2016
A Hydrogel-Based Epirubicin Delivery System for Intravesical ChemotherapyChing-Wen Liu, Yu-Tse Wu, Kai-Jen Lin, et al.
Urologic Oncology|December 20, 2011
Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosisHung-Yu Lin, Ming-Chang Yang, Chun-Hsiung Huang, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Pediatric Transplantation|October 4, 2007
De novo urothelial carcinoma in a pediatric recipient of living donor kidney graftChan-Yao Wu, Shih-Yuan Hung, Yu-Tsun Su, et al.
Molecules (Basel, Switzerland)|November 11, 2022
WWOX Modulates ROS-Dependent Senescence in Bladder CancerChing-Wen Liu, Po-Hen Chen, Tsan-Jung Yu, et al.
Journal of Clinical Nursing|December 20, 2011
Comparison of health-related quality of life between subjects treated with radical prostatectomy and brachytherapyYu-Hua Lin, Victor Chia-Hsiang Lin, Tsan-Jung Yu, et al.
Cancer Nursing|October 23, 2012
Changes in quality of life among prostate cancer patients after surgeryYu-Hua Lin, Tsan-Jung Yu, Victor Chia-Hsiang Lin, et al.
Urology|February 20, 2004
Synchronous bilateral primary transitional cell carcinoma of the upper urinary tracts: ten patients with more than five years of follow-upChih-Hsiung Kang, Tsan-Jung Yu, Hwei-Ho Hsieh, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 11, 2004
High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablationPo Hui Chiang, Fu Min Fang, Wang Chong Jong, et al.
Oncology Reports|December 28, 2011
p53 codon 72 polymorphism as a progression index for bladder cancerHung-Yu Lin, Chun-Hsiung Huang, Tsan-Jung Yu, et al.
Urologia Internationalis|February 25, 2011
p53 codon 72 polymorphism was associated with vulnerability, progression, but not prognosis of bladder cancer in a Taiwanese population: an implication of structural equation modeling to manage the risks of bladder cancerHung-Yu Lin, Chun-Hsiung Huang, Tsan-Jung Yu, et al.
Molecules (Basel, Switzerland)|June 4, 2016
A Hydrogel-Based Epirubicin Delivery System for Intravesical ChemotherapyChing-Wen Liu, Yu-Tse Wu, Kai-Jen Lin, et al.
Urologic Oncology|December 20, 2011
Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosisHung-Yu Lin, Ming-Chang Yang, Chun-Hsiung Huang, et al.
Pageof 3